| Experienced management and established track record of operations:
Hyderabad-based Virinchi Limited (VL) was incorporated in 1990 by Mr. Vishwanath Kompella and is engaged in providing IT-based products and services to fintech companies. The company’s flagship product, Q-Fund, is widely used by alternate finance companies in North America to provide short-term financing to sub-prime customers. In 2016, Virinchi Health Care Private Limited was incorporated as a subsidiary of VL, with an initial hospital capacity of 350 beds in Hyderabad, which has since been expanded to 600 beds. The Virinchi Group (VG), promoted by Mr. Vishwanath Kompella, benefits from his over three decades of experience across the IT and healthcare sectors. With an established presence of more than three decades in the IT industry, VL’s revenues are entirely export-oriented, primarily catering to the North American market. Acuité believes that the Group’s long operating track record, strong industry positioning, and promoter experience are expected to support a stable flow of revenues over the medium term.
Above average financial risk profile:
Financial risk profile of the group is marked by comfortable net worth, moderate gearing and debt protection metrics. Group’s net worth stood at Rs. 330.35 Cr. as on March 31, 2026 compared to Rs. 319.09 Cr. as on March 31, 2025. The improvement in networth despite net loss during the year is on account of equity infusion and adjustment in the intangible assets during the year. Virinchi group’s debt position stood at Rs.273.38 Cr. as on March 31, 2026 (comprising finance lease liability, term loans, unsecured loans, short-term debt and current maturities of long-term debt) as against Rs.292.49 Cr. as of previous year end. The gearing remained healthy at 0.83 times as on March 31, 2026 as against 0.92 times as on March 31, 2025. The total outside liabilities to total net worth (TOL/TNW) also remained healthy at 1.11 times as on March 31, 2026 as against 1.17 times as on March 31, 2025. The debt protection metrics have remained moderate with interest coverage ratio (ICR) of 2.01 times and debt service coverage ratio (DSCR) of 1.03 times as on March 31st 2025. Debt to EBITDA stood at 4.31 times as on March 31, 2026 against 3.01 times as of March 31, 2024. Acuite believes that the financial risk profile of the company will remain above average over the near term in the absence of large debt funded capex.
|
| Moderation in revenue and profitability:
The group's operating performance moderated during FY2026, with operating income declining to Rs.284.36 Cr. from Rs.301.13 Cr. in FY2025, primarily due to lower contribution from the Healthcare Services segment. Consequently, EBITDA declined to Rs.69.73 Cr. in FY2026 from Rs.90.01 Cr. in FY2025, with EBITDA margin moderating to 24.52 percent from 29.89 percent over the same period. The group reported a net loss of Rs.27.39 Cr. in FY2026 against a marginal profit of Rs.0.48 Cr. in FY2025. The operating profit margins declined to 24.52 percent in FY2026 from 29.89 percent in FY2025, impacted by non-recurring items, including bad-debts written off and prior period expenses during FY2026. During Q1FY2027, consolidated operating income declined on a year-on-year basis to Rs.70.13 Cr. from Rs.79.74 Cr. in Q1FY2026, primarily due to lower revenues from the Healthcare Services segment. The profitability (EBIT) in Q1FY2027 stood at Rs.1.39 Cr. compared to Rs.(11.73) Cr. during Q1FY2026. However, on a sequential basis, the group's performance witnessed moderate improvement, with operating income increasing from Rs.65.97 Cr. in Q4FY2026 to Rs.70.13 Cr. in Q1FY2027 and losses narrowing during the quarter. The improvement was supported by growth in the SaaS business and higher healthcare revenues on a sequential basis. However, profitability remained constrained by continued losses in the Healthcare Services segment due to investments towards strengthening clinical capabilities and business development initiatives. Acuité believes that the group's ability to improve the operating performance of the healthcare business while maintaining growth in the SaaS segment will remain a key monitorable.
Intensive working capital operations:
The working capital operations of the group remained intensive which is evident from the Gross Current Assets (GCA) of 287 days in FY2026 as against 201 days in FY2025. Stretch in GCA is mainly on account of elongated debtor days to 111 days in FY2026 from 98 days in FY2025 along with increased other current assets during the year. Receivable period in healthcare segment is generally stretched as the recovery from general insurance, ESI and government’s schemes takes 3-4 months to recover. However, debtors in I.T business will be recovered in 30-45 days. The creditor days stood at 350 days in FY2026 as against 209 days in FY2025. Acuite believes that working capital operations of the group will remain intensive over the medium term as the nature of its operations.
Highly competitive industry and stringent regulatory framework, reputational intensive healthcare sector.
IT industry is characterized by intense competition from large players enjoying benefits and higher bargaining power. The company also remains susceptible to industry-specific risks, such as exchange-rate fluctuations. However, the entrepreneurial experience is supporting its operating margins. Further, despite the increasing trend of privatization of healthcare sector in India, the group continues to operate under stringent regulatory control. Accordingly, regulatory challenges continue to pose a significant risk to private healthcare institutions, as they are highly susceptible to changes in regulatory framework. Healthcare is a highly sensitive sector, where any mishandling of a case or negligence on the part of any doctor and/or staff of the unit can lead to distrust among the masses. Thus, all the healthcare providers need to monitor each case diligently and maintain standard of services in order to avoid the occurrence of any unforeseen incident. They also need to maintain high vigilance to avoid any malpractice at any pocket.
|
